| Autor: |
Camacho-Neciosup, Rodrigo, Balcazar-Huaman, Ericka N., Alvarez-Vilchez, Margarita L., De la Cruz-Galán, Janith P., Gálvez-Guadalupe, Yubely, Garcia-Muñoz, Edwin D., Cerron-Daga, Greysi, Failoc-Rojas, Virgilio E., Valladares-Garrido, Mario J. |
| Předmět: |
|
| Zdroj: |
PeerJ; Mar2024, p1-26, 26p |
| Abstrakt: |
Introduction. The pandemic of COVID-19 continues to impact people worldwide, with more than 755 million confirmed cases and more than 6.8 million reported deaths. Although two types of treatment, antiviral and immunomodulatory therapy, have been approved to date, vaccination has been the best method to control the spread of the disease. Objective. To explore factors associated with the intention to be vaccinated with the COVID-19 booster dose in Peru. Material and Methods. Cross-sectional study, using virtual and physical surveys of adults with two or more doses of COVID-19 vaccine, where the dependent variable was the intention to be vaccinated (IBV) with the booster dose. We calculated prevalence ratios with 95% confidence intervals, using generalized linear models of the Poisson family with robust varying, determining associations between sociodemographic, clinical, and booster dose perception variables. Results. Data from 924 adults were analyzed. The IBV of the booster doses was 88.1%. A higher prevalence was associated with being male (aPR = 1.05; 95% CI [1.01-1.10]), having a good perception of efficacy and protective effect (PR = 3.69; 95% CI [2.57-5.30]) and belonging to the health sector (PR = 1.10; 95% CI [1.04-1.16]). There was greater acceptance of the recommendation of physicians and other health professionals (aPR = 1.40; 95% CI [1.27-1.55]). Conclusions. Factors associated with higher IBV with booster dose include male gender, health sciences, physician recommendation, and good perception of efficacy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
